Document is current
Any future updates will be listed below
-
Authors
Gilmore, Christopher A. https://orcid.org/0000-0002-8001-6867
Deer, Timothy R. https://orcid.org/0000-0001-8907-7730
Desai, Mehul J. https://orcid.org/0000-0001-6870-9436
Li, Sean https://orcid.org/0000-0002-0492-1179
DePalma, Michael J. https://orcid.org/0000-0003-1532-3438
Cohen, Steven P. https://orcid.org/0000-0001-5928-2127
Swan, Brandon D. https://orcid.org/0000-0001-5960-6822
McGee, Meredith J. https://orcid.org/0000-0003-0823-3362
Boggs, Joseph W. https://orcid.org/0000-0002-7973-7990
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03179202 at ClinicalTrials.govDocuments that mention this clinical trial
Four-Year Follow-Up from a Prospective, Multicenter Study of Percutaneous 60-Day Peripheral Nerve Stimulation for Chronic Low Back Pain
https://doi.org/10.1007/s40122-025-00737-3
-
Funding
Funding for this research was provided by:
SPR Therapeutics
- License Information
-
More Information
Article History
Received: 28 February 2025
Accepted: 27 March 2025
First Online: 22 April 2025
Declarations
:
: The authors declare the following conflicts of interest in connection with the submitted material: Christopher A. Gilmore, Timothy R. Deer, Mehul J. Desai, Sean Li, and Michael J. DePalma have research sponsored by SPR Therapeutics; Christopher A. Gilmore, Timothy R. Deer, Mehul J. Desai, and Sean Li are consultants for SPR; Brandon D. Swan, Meredith J. McGee, and Joseph W. Boggs are employees of and named on patents assigned to SPR Therapeutics; and Timothy R. Deer, Mehul J. Desai, Meredith J. McGee, and Joseph W. Boggs have stock options in SPR Therapeutics.
: This follow-up survey was completed as a protocol addendum to a prior prospective multicenter case series study protocol, which was approved by an institutional review board (IRB; Quorum Review IRB, now Advarra, Seattle, WA, USA) and was registered on ClinicalTrials.gov (NCT03179202). The initial prospective study followed good clinical practice and was conducted within the ethical guidelines outlined in the Declaration of Helsinki. Prior to participation in the initial prospective study, participants provided written informed consent. The follow-up survey and protocol addendum were reviewed by the IRB and determined to meet exemption criteria.
